ArticleBMC cancer2026
Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHER2 overexpression or ERBB2 amplification represents an important molecular feature of urothelial carcinoma (UC) and has been associated with differential responses to immune checkpoint inhibitors (ICIs). However, the tumor microenvironmental (TME) features associated with HER2-defined UC and their potential relationship with ICI responsiveness remain incompletely characterized.
methodsTumor tissues from 52 UC patients treated with ICIs monotherapy at our center underwent multiplex immunofluorescence (IF) staining to evaluate immune cell infiltration and immune checkpoint protein expression. In parallel, transcriptomic and somatic mutation data from 408 UC cases in The Cancer Genome Atlas (TCGA) were analyzed. Differential gene expression and pathway enrichment analyses were performed based on HER2 copy number status (GISTIC score ≥ 2 for amplification). The xCell algorithm was used to estimate immune cell infiltration in bulk RNA-seq data.
resultsIn the institutional cohort, HER2-positive tumors showed numerically lower objective response rate (ORR) and disease control rate (DCR) than HER2-negative tumors, although these differences were not statistically significant. Multiplex IF analysis revealed reduced infiltration of CD4⁺ T cells, CD8⁺ T cells, and CD20⁺ B cells in HER2-positive tumors. PD-1 and STING expression were also lower in HER2-positive tumors, whereas LAG-3, TIM-3, CTLA-4, and PD-L1 showed non-significant downward trends. In the TCGA-BLCA cohort, ERBB2-amplified tumors showed downregulation of immune-related pathways and reduced inferred infiltration of multiple immune cell populations, including T cells, dendritic cells, B cells, NK cells, and macrophages.
conclusionsHER2-positive UC in the institutional IHC-defined cohort and ERBB2-amplified UC in the TCGA cohort were associated with reduced adaptive immune infiltration and attenuated immune-related signaling. These findings support the presence of an immune-cold phenotype in HER2-defined UC and provide hypothesis-generating evidence for further investigation of biomarker-guided combination strategies integrating HER2-targeted therapy with immune checkpoint blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.